TEL AVIV July 12 (Reuters) - Israeli drug development company BioLineRx (BLRX.TA) is planning a share offering on U.S. exchange Nasdaq, the company said on Monday.
BioLineRx said its board has decided to advance the process and has called a shareholders' meeting to approve certain measures that must be taken.
The company has already started preparations for an offering and submitted confidential filings to the U.S. Securities and Exchange Commission, BioLineRx said in a statement to the Tel Aviv Stock Exchange.
The next filing is expected to be public, it added.
"It should be clear that the timing, size and structure of the offering have not been finalised," the statement said.
BioLineRx signed a $365 million out-licensing deal last month with Cypress Bioscience (CYPB.O) for its anti-psychotic drug BL-1020.
Last year New Jersey-based Ikaria Holdings Inc agreed to pay $285 million for a license to develop and market BioLineRx's BL-1040 drug for heart attack patients.
BL-1040 is a myocardial implant for the treatment of acute myocardial infarction.
Market Data 
Markets 
AI
